OpenBilldrug price receipt

NADAC week of 2026-10-14

ALOGLIPTIN 12.5 MG TABLET

For 30 tablets

Pharmacies pay

$148.70 filed

30 × $4.95683 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$159.54 filed

30 × $5.31792 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.1× estimated

Medicare paid 1.1× what pharmacies pay.

Part D averages every strength and form sold under “Alogliptin” / “Alogliptin Benzoate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$176.01 estimated

$148.70 + $22.31 (15%) + $5.00 fee per fill = $176.01

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ALOGLIPTIN 12.5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as alogliptin.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Padagis Israel Pharmaceuticals Ltd.

FDA’s Established Pharmacologic Class for it is Dipeptidyl Peptidase 4 Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 45802-0103-65.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $148.70 for 30 tablets (30 × $4.95683 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The NDC

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name alogliptin with ALOGLIPTIN 12.5 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
ALOGLIPTIN 6.25 MG TABLET
generic · tablet, film coated
$5.27823 per EA filed
eff. 2026-09-23
$5.31792 per EA filed
Part D 2024 average
ALOGLIPTIN 12.5 MG TABLET this page
generic · tablet, film coated
$4.95683 per EA filed
eff. 2026-09-23
$5.31792 per EA filed
Part D 2024 average
ALOGLIPTIN 25 MG TABLET
generic · tablet, film coated
$4.9069 per EA filed
eff. 2026-09-23
$5.31792 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $4.95683 per EA filed.

Of the 43 other products in FDA’s Dipeptidyl Peptidase 4 Inhibitor class priced per EA, 32 have a higher middle NADAC price and 11 a lower one. The one in the middle is TRIJARDY XR 12.5-2.5-1,000 MG, at $5.62766 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $159.54 for 30 tablets, at an average of $5.31792 per EA in 2024 (2024-01-01 to 2024-12-31) for “Alogliptin” and “Alogliptin Benzoate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 76,792 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for ALOGLIPTIN 12.5 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Alogliptin / Alogliptin Benzoate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.